On November 26, Standard Robots and Qingdao Haier Biomedical Co., Ltd. (hereinafter referred to as "Haier Bio") signed a strategic cooperation agreement. The two parties will carry out in-depth cooperation in all-round, multi-level and wide-ranging fields around key areas such as the popularization and application of robots in smart medical scenarios.
Standard Robots is an industry-leading industrial mobile robot R&D and production company. As a leader in the AMR industry, it has achieved full coverage of independent research and development of core technologies such as robot positioning and navigation algorithms, operation and scheduling systems, and controllers. Its products have been used in China, the United States, Japan, Europe, the Middle East, Southeast Asia and other countries and regions, and serve many industries such as 3C, medical and pharmaceutical, semiconductors, photovoltaics, lithium batteries, panels, and automotive parts.
Haier Bio is a global leading provider of comprehensive IoT biosafety solutions. Its innovative biomedical scenarios have been used in more than 120 countries and regions around the world, covering tens of thousands of domestic hospitals, biotechnology companies, university research institutions, disease control, plasma stations, testing institutions and other medical and health end users.
In this strategic cooperation, Haier Bio will introduce Standard Robots's artificial intelligence technology into its blood component preparation, drug management and other scenarios to promote the popularization and application of robots in smart medical scenarios and accelerate the digitalization, unmanned and convenient upgrade of IoT biosafety digital medical solutions.
Standard Robots CEO Wang Yongkun said: "Standard Robots's integration into Haier Bio's smart medical scenarios will bring safer, more accurate and efficient scenario solutions to the medical field, and will effectively promote the digitalization of medical scenario management in my country."
Haier Bio Deputy General Manager Chen Haitao said: "Standard Robots and Haier Bio will give full play to their respective technical advantages to accelerate the intelligent, digital and unmanned development of urban blood management and drug management, and further promote the new digital medical infrastructure while achieving cost reduction and efficiency improvement."
As leaders in their respective fields, the two parties have strong complementary advantages and a good foundation for cooperation. Comprehensive strategic cooperation will also add new impetus for Stand Robot to promote the construction of a healthy China. In the future, the two parties will continue to expand the depth and breadth of cooperation and jointly create high-quality smart medical services.
